Peripheral intravenous norepinephrine

Phase 3Small molecule

Peripheral intravenous norepinephrine is one of 34 small molecule programs targeting Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionRecruiting

HypertensionPhase 3

Recruiting

Competition

Competitive Landscape

157 competitors in Hypertension

#DrugCompanyPhaseTrials

Baxfendy

AstraZeneca

Phase 3

3 2

Foundayo

Eli Lilly

Phase 3

3 3

Nitrostat

VViatris Specialty LLC

Phase 3

5 4

Alka-Seltzer

AAbbott

Phase 3

1 5

Peripheral intravenous norepinephrine

UUniversity Hospital, Bordeaux

Phase 3

1 6

HCP1803-3

Hanmi Pharmaceutical Company Limited

Phase 3

1 7

SGLT2

PProf. Dr. med. Ingo Eitel

Phase 3

1 8

Avastin

Roche

Preclinical

1 9

Winrevair

Alphagan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Hypertension

NCT06059144

Clinical

Trials by Indication[1]

Hypertension1 trial

Induced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine

Recruiting·UUniversity Hospital, Bordeaux·Phase 3·NCT06059144·358 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Peripheral intravenous norepinephrine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peripheral intravenous norepinephrine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peripheral intravenous norepinephrine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Bordeaux company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Bordeaux

Peripheral intravenous norepinephrine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Hypertension1 trial

References

Drug Info

Quick Facts

Related News